Adaptive Biotechnologies Corporation — Quarterly Cash Flow (NASDAQ:ADPT) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Total assets 558.51 M539.38 M510.85 M496.64 M490.61 M512.74 M Total liabilities 334.93 M336.89 M320.63 M317.1 M286.36 M287.74 M Total equity 223.57 M202.49 M190.22 M179.54 M204.25 M225 M Total liabilities & shareholders' equities 558.51 M539.38 M510.85 M496.64 M490.61 M512.74 M Total debt —————— Net debt ——————

Nouvelles

3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts - TipRanks.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adeptus Biotechnologies stock price target raised to $21 by TD Cowen

Thursday’s Insider Activity: Cavco Director Buys as Execs Sell Off

Adaptive Biotechnologies Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ADPT) 2026-02-06

L’objectif de prix de l’action Adeptus Biotechnologies relevé à 22$ par BTIG

Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies T4 2025 : croissance de 55% du chiffre d’affaires avec l’expansion de l’activité MRD

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

Adaptive Biotechnologies s’envole après avoir dépassé les attentes du T4

Les résultats d’Adaptive Biotechnologies à venir : cap sur la rentabilité